Roman Rodionov: Is Lp(a) Another Homocysteine?
Roman Rodionov, Senior Consultant (Internal and Vascular Medicine, Apheresis), Head of the Angiology Research Lab at Dresden University of Technology, shared a post on LinkedIn:
“Is Lp(a) another homocysteine?
Remember the excitement around homocysteine?
Strong epidemiological associations, plausible biology – but lowering homocysteine ultimately failed to reduce cardiovascular events.
The enthusiasm around Lp(a) over the last year has been remarkable.
We have heard the word causal a lot – while still waiting for the ultimate clinical test: will lowering Lp(a) actually reduce cardiovascular events?
Now Lp(a) HORIZON with pelacarsen has not met its primary endpoint, despite lowering Lp(a).
Does this make Lp(a) another homocysteine?
Probably too early to say.
We need the full results, and other outcome trials are coming.
But more interesting question is: what will be the next big target for residual cardiovascular risk?”
Stay updated with Hemostasis Today.
-
Sep 8, 2026, 12:48Denis Oduor: Beyond the Donation Chair and Into a Legacy of Hope
-
Sep 8, 2026, 12:24Alejandro González Veliz: Can a Stent Cause a Heart Attack?
-
Sep 8, 2026, 11:15Andreas Tridimas: Atherosclerosis Is Greyer Than We Admit
-
Sep 8, 2026, 10:59Eman M. Elsabbagh: Pediatric Nonmalignant HCT Enters the Era of Precision Conditioning and Gene Therapy
-
Sep 8, 2026, 10:50Dena Winchester: Sponsored Genetic Testing Programs Improve Access for Children With Hemophilia A
-
Sep 8, 2026, 10:49Alessandra Bosch: Von Willebrand Disease and Rare Bleeding Disorders, Collaborative Insights and Patient Empowerment
-
Sep 8, 2026, 09:42Vineet Sankhla: Rethinking Potent P2Y12 Inhibition in AF Patients Undergoing PCI
-
Sep 8, 2026, 09:23Mehdi Mirsaeidi: Platelets and Thromboinflammation in COPD
-
Sep 8, 2026, 09:03Michel Cabrera Ortega: LAAC vs OAC – Which Risk Are We Trading?